Skip to main content
Cisen Pharmaceutical Co.,Ltd. logo

Cisen Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 603367 ISIN · CNE100002VG4 LEI · 836800T7RRJXURVHYS35 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,110 across all filing types
Latest filing 2024-05-09 Call Transcript
Country CN China
Listing Shanghai Stock Exchange 603367

About Cisen Pharmaceutical Co.,Ltd.

https://www.cisen-pharma.com/

Cisen Pharmaceutical Co.,Ltd. is a comprehensive enterprise dedicated to the research, development, production, and marketing of a diverse range of medicinal products. The company specializes in the manufacture of large-volume injections, small-volume injections, and solid oral dosage forms, including tablets and capsules. Its product portfolio addresses critical therapeutic areas such as parenteral nutrition, anti-infectives, cardiovascular health, and anesthesia. Cisen Pharmaceutical maintains an integrated value chain, producing both active pharmaceutical ingredients (APIs) and finished formulations. The organization emphasizes technological innovation and stringent quality management systems to ensure the efficacy and safety of its medical solutions. By leveraging advanced manufacturing capabilities and a robust distribution network, the company provides essential healthcare products to clinical institutions and medical providers.

Recent filings

Filing Released Lang Actions
辰欣药业股份有限公司关于2023年度暨2024年第一季度业绩说明会召开情况的公告
Call Transcript Classification · 90% confidence The document is an announcement about the holding of a performance briefing session (业绩说明会) for the 2023 fiscal year and the first quarter of 2024. It includes a summary of questions from investors and the company's responses, covering topics such as sales, R&D, product registration, financial performance highlights, and ESG-related questions. The document does not contain detailed financial statements or comprehensive financial data typical of an Interim/Quarterly Report (IR). Instead, it reports on the occurrence and content of an earnings explanation meeting, which is consistent with a Call Transcript (CT) or an Earnings Release (ER). However, the format is a Q&A summary from an earnings briefing rather than a full earnings release or transcript of a conference call. Given the nature of the document as a summary of an earnings explanation meeting with Q&A, the best fit is Call Transcript (CT). The document length is under 5,000 characters, but it contains substantive Q&A content rather than just an announcement of a report publication, so it is not an RPA. Therefore, the classification is CT with high confidence.
2024-05-09 Chinese
辰欣药业股份有限公司关于持股5%以上股东集中竞价减持股份计划
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding a major shareholder's plan to reduce their shareholding through centralized bidding. It details the shareholder's current holdings, the planned reduction amount, timing, and related commitments. The text includes specific shareholding percentages, reduction plans, and regulatory compliance statements. There are no financial statements, earnings data, or management discussions. The document is a formal disclosure of a significant shareholder's share reduction plan, which fits the definition of a Major Shareholding Notification (MRQ). The document length is 2809 characters, which is typical for such announcements. Therefore, the appropriate classification is MRQ with high confidence.
2024-05-09 Chinese
北京市盈科（济南）律师事务所关于辰欣药业股份有限公司实际控制人、董事长兼总经理增持公司股份的专项核查意见
Regulatory Filings
2024-05-06 Chinese
辰欣药业股份有限公司关于实际控制人、董事长兼总经理增持股份计划实施完毕暨增持结果的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the completion and results of a shareholding increase plan by the company's actual controller and chairman. It details the shareholding before and after the increase, the amount and percentage of shares acquired, the legal compliance of the transaction, and includes a lawyer's opinion on the legality of the share increase. There are no financial statements or performance data, nor is this a report or presentation. The content fits the category of a transaction involving the company's own shares, specifically a share repurchase or shareholding increase by insiders. Therefore, the document is best classified as a Transaction in Own Shares (POS). The document length is 2734 characters, which is consistent with an announcement rather than a full report.
2024-05-06 Chinese
辰欣药业股份有限公司2023年度独立董事述职报告（张宏）
Board/Management Information Classification · 95% confidence The document is titled '2023年度独立董事述职报告' which translates to '2023 Annual Independent Director's Work Report' for the company 辰欣药业股份有限公司. It details the independent director's duties, attendance at board and committee meetings, communication with auditors, oversight of financial reporting, internal controls, related party transactions, and other governance matters during the 2023 fiscal year. The document is a detailed report on the independent director's activities and governance oversight rather than a general annual report or financial statement. It focuses on board/management information, specifically the independent director's role and performance. There is no indication that this is an annual report (10-K), audit report (AR), or other financial report. It is not a brief announcement or voting result. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (6627 characters) and content support this classification with high confidence.
2024-04-22 Chinese
辰欣药业股份有限公司2023年年度报告
Annual Report Classification · 100% confidence The document is titled "2023 年年度报告" which translates to "2023 Annual Report". It is issued by 辰欣药业股份有限公司 (Cisen Pharmaceutical Co., Ltd.) and covers the fiscal year from January 1, 2023 to December 31, 2023. The document contains detailed sections including company overview, management discussion and analysis, financial data, audit report mention, governance, environmental and social responsibility, and other comprehensive information typical of a full annual report. The length is substantial (15,000 characters) and it includes actual financial data, management analysis, and audit opinions. It is not a brief announcement or a certification letter but a full detailed report. Therefore, it fits the definition of an Annual Report (10-K). FY 2023
2024-04-22 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.